57711-36-1

Upstream product

• 57711-34-9 4-Hydroxy-5,6-dihydrobenzoquinazoline 

Downstream Products

• 96840-48-1 4-benzamido-5,6-dihydrobenzoquinazoline 
• 96861-07-3 1-acetoxy-2-benzyl-4,5-dihydrobenzimidazo<1,2-c>quinazoline 
• 96840-47-0 1-acetoxy-2-phenyl-5,6-dihydrobenzimidazo<1,2-c>quinazoline 
• 374555-71-2 N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 
• 1163785-05-4 N-(4-tert-butylphenyl)-5,6-dihydrobenzo[h]quinazolin-4-amine 
• 374555-69-8 N-[3-chloro-5-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-5,6-dihydrobenzo[h]quinazolin-4-amine 
• 374556-66-8 N-{3-[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-1H-imidazol-1-yl]phenyl}-5,6-dihydrobenzo[h]quinazolin-4-amine 
• 96838-10-7 N-(5,6-dihydro-4-benzoquinazolinyl)phenylglycine 
• 96838-09-4 N-(5,6-dihydro-4-benzoquinazolinyl)phenylalanine 

Relevant academic research and scientific papers

SUBSTITUTED TRICYCLIC PYRIDINE OR PYRIMIDINE VANILLOID RECEPTOR LIGANDS

The present invention relates to substituted tricyclic compounds, which can be used as vanilloid receptor ligands. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by vanilloid receptor-1 (VRl). Also provided herein are pharmaceutical compositions and methods for treating or preventing diseases, conditions and/or disorders modulated by VRl.